Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Jun 5 2010

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare^® Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command. The Calmare Pain Therapy Treatment will be used to treat wounded warriors and other military personnel who are suffering from neuropathic pain.

"We are pleased to have this opportunity to make a difference in the lives of those who have given so much in defense of our great nation," said John B. Nano, CTT's Chairman, President and CEO. "With over 60% of our returning veterans suffering from significant pain, as reported at last month's American Pain Society annual meeting, we are glad to be able to offer these wounded warriors and their physicians a non-invasive pain relief option without the harmful, adverse side effects associated with powerful opioids, such as morphine. Calmare Pain Therapy successfully treats chronic neuropathic pain resulting from phantom limb syndrome, shingles, failed back surgery, sciatica, spinal stenosis and other maladies."

"As a veteran, I am thrilled to see Walter Reed Army Medical Center added to the growing number of respected medical institutions treating patients with CTT's Calmare Pain Therapy," said Jean Wilczynski of IR Services, LLC. "I believe it is of utmost importance that our wounded warriors and service members suffering from serious injuries and severe, debilitating pain be provided with the best possible treatment options, especially those that can help them avoid the harmful side effects of powerful opioids and other medications." 

Calmare is currently being used at the Virginia Commonwealth University Massey Cancer Center, the Paul Carbone Cancer Center at the University of Wisconsin, Madison, and the University of Miami Pain Management Center. Calmare is also being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island. 

The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is currently manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales.